Etirinotecan Pegol (<scp>NKTR</scp>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
This study demonstrates that EP did not meet the threshold of clinical efficacy in patients with refractory CNS metastases from lung or breast cancer.
Authors
- Gwen Coffey
- Sophie Bertrand (ORCID: https://orcid.org/0000-0003-1976-3799)
- Seema Nagpal (ORCID: https://orcid.org/0000-0002-0289-2319)
- Joshua James Gruber (ORCID: https://orcid.org/0000-0002-8642-6074)
- Mark D. Pegram (ORCID: https://orcid.org/0000-0002-9743-8118)
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Lawrence David Recht (ORCID: https://orcid.org/0000-0001-8614-2189)
- Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
- Judy Y. Pagtama
- Melinda L. Telli (ORCID: https://orcid.org/0000-0001-7993-1235)
- Sukhmani K. Padda (ORCID: https://orcid.org/0000-0002-8691-7754)
- Alison Holmes Tisch (ORCID: https://orcid.org/0000-0002-6537-1035)
- Kristen May Cunanan (ORCID: https://orcid.org/0000-0001-9873-9214)
- George W. Sledge (ORCID: https://orcid.org/0000-0003-0297-0775)
- Scott Gerard Soltys (ORCID: https://orcid.org/0000-0002-5360-7063)
- Kim-Son H. Nguyen
- Reena Thomas (ORCID: https://orcid.org/0000-0002-2695-3462)
- Suleiman Massarweh
Institutions
- Fox Chase Cancer Center (US)
- Southwestern Medical Center (US)
- Stanford Health Care (US)
- Temple University Health System (US)
- Stanford Medicine (US)
- Southwestern Medical Center (US)
- Temple University (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1002/cnr2.70330
- Citations
- 1
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52